NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

A single-number metric from a handheld device outperformed dozens of other measurements for the prediction of ...

Treatment with the investigational psychedelic GH001 was linked with significant improvements in TRD that persist for at ...

Miracles by definition defy science. But a new research effort attempts to understand what our experiences with them do to ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk ...

Crawford, a medical oncologist at Duke Cancer Center and Duke Cancer Center Thoracic Clinic in Durham, North Carolina, ...

I am a 66-year-old male who often experiences achiness in my lower joints (hip arthritis and occasional knee pain).

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Praxis Precision surges on positive ulixacaltamide data for essential tremor, but tolerability limits impact. Explore PRAX's ...

Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...